Intelligent Bio Solutions earnings release, August 19, 2026
Exhibit
99.1
Intelligent
Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge
Growth
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year
502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries
Company made substantial progress toward FDA clearance and planned market expansion during the year
NEW
YORK, August 19, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the full year ended June 30, 2026, and provided a business update.
“Fiscal
2026 was a year of clear, compounding progress across every aspect of our business,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “We delivered record annual revenue of $4.2 million, a 38% increase year-over-year, driven by a 22% expansion in our reader installed base and a 35% increase in consumable cartridges. Our razor-razorblade model is gaining scale, with hardware placements generating the installed base and growing consumable utilization delivering recurring revenue. Entering fiscal
2027, we are focused on three priorities: sustaining the operational improvements driving gross margin expansion, continuing to accelerate commercial growth, and advancing our FDA regulatory program toward planned U.S. market entry. To that end, we have completed all clinical data collection across our FDA 510(k) clinical study program. Analysis of collected data is underway, and we remain on track for our
FDA submission.”
“The financial results for fiscal 2026 reflect a business that is scaling with improving unit economics,” said Spiro Sakiris, CFO at Intelligent Bio Solutions. “Full-year gross profit grew 64% to $2.05 million and gross margin expanded 778 basis points to
48.63%. These improvements are a result of our transition to Syrma Johari as a high-quality, lower-cost manufacturing partner, an optimized product mix weighted toward higher-margin cartridge consumables, and the operational leverage that comes from growing volumes across a more efficient production base. Our sustained investment in marketing, sales, product awareness, and customer support has been the direct commercial driver behind our 38% revenue growth and the expanding utilization we are seeing across our installed base.”
Full
Year Fiscal 2026 Financial Highlights
Progress
Toward FDA Clearance and U.S. Market Expansion
INBS made substantial progress throughout fiscal 2026 in advancing its FDA 510(k) submission, supporting its planned entry into the multi-billion-dollar
U.S. drug screening market beyond current Forensic Use Only settings. The Company’s regulatory program accelerated significantly, underpinned by a series of clinical and technical studies:
Commercial
Growth and Market Expansion
INBS continued to expand its commercial presence across international markets throughout fiscal 2026, supported by targeted investment in marketing, sales, and customer support infrastructure.
Operational
Efficiencies Strengthening Business Fundamentals
The improvement in gross profit margin from 40.85% to 48.63% year-over-year reflects the structural progress INBS has made in its production and commercial operations throughout fiscal 2026:
About
Intelligent Bio Solutions Inc.
Intelligent
Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The
Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
Forward-Looking
Statements
Financial statements
Income Statement
Year ended June 30, — Consolidated Statements of Operations and Other Comprehensive Income (Loss)
| Year ended June 30, – 2026 | Year ended June 30, – 2025 | ||
|---|---|---|---|
| Revenue | 4,215,175 | 3,052,532 | |
| Cost of revenue (exclusive of amortization shown separately below) | -2,165,181 | -1,805,673 | |
| Gross profit | 2,049,994 | 1,246,859 | |
| Other income | Government support income | 677,776 | 816,901 |
| Operating expenses | Selling, general and administrative expenses | -10,502,161 | -8,918,468 |
| Operating expenses | Development and regulatory approval expenses | -3,371,292 | -2,396,513 |
| Operating expenses | Depreciation and amortization | -1,163,847 | -1,207,875 |
| Operating expenses | Impairment of long-lived assets | -298,555 | -220,062 |
| Operating expenses | Total operating expenses | -15,335,855 | -12,742,918 |
| Operating expenses | Loss from operations | -12,608,085 | -10,679,158 |
| Other income (expense), net | Interest expense | -10,736 | -26,339 |
| Other income (expense), net | Realized foreign exchange gain (loss) | 39,820 | -911 |
| Other income (expense), net | Interest income | 110,329 | 101,522 |
| Other income (expense), net | Total other income, net | 139,413 | 74,272 |
| Other income (expense), net | Net loss | -12,468,672 | -10,604,886 |
| Other income (expense), net | Net loss attributable to non-controlling interest | -37,697 | -36,153 |
| Other income (expense), net | Net loss attributable to Intelligent Bio Solutions Inc. | -12,430,975 | -10,568,733 |
| Other comprehensive (loss) income | Foreign currency translation (loss) gain | -218,242 | 384,670 |
| Other comprehensive (loss) income | Total other comprehensive (loss) income | -218,242 | 384,670 |
| Other comprehensive (loss) income | Comprehensive loss | -12,686,914 | -10,220,216 |
| Other comprehensive (loss) income | Comprehensive loss attributable to non-controlling interest | -37,697 | -36,153 |
| Other comprehensive (loss) income | Comprehensive loss attributable to Intelligent Bio Solutions Inc. | -12,649,217 | -10,184,063 |
| Other comprehensive (loss) income | Net loss per share, basic and diluted* | -8.44 | -20.04 |
| Other comprehensive (loss) income | Weighted average shares outstanding, basic and diluted* | 1,472,744 | 527,364 |
Balance Sheet
As of June 30, — Consolidated Balance Sheets
| As of June 30, – 2026 | As of June 30, – 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 3,992,312 | 1,019,909 |
| Current assets | Accounts receivable, net | 848,464 | 594,614 |
| Current assets | Inventories, net | 418,577 | 635,215 |
| Current assets | Research and development tax incentive receivable | 806,951 | 734,408 |
| Current assets | Assets held for sale | 327,500 | |
| Current assets | Prepaid expenses and other current assets | 1,030,932 | 826,976 |
| Current assets | Total current assets | 7,097,236 | 4,138,622 |
| Current assets | Property and equipment, net | 294,399 | 251,325 |
| Current assets | Operating lease right-of-use assets | 1,751,040 | 69,520 |
| Current assets | Intangibles, net | 2,799,161 | 3,790,319 |
| Current assets | Total assets | 11,941,836 | 8,249,786 |
| Current liabilities | Accounts payable and accrued expenses | 4,130,213 | 4,534,246 |
| Current liabilities | Current portion of operating lease liabilities | 147,005 | 84,659 |
| Current liabilities | Current employee benefit liabilities | 651,706 | 534,990 |
| Current liabilities | Notes payable | 197,146 | |
| Current liabilities | Total current liabilities | 4,928,924 | 5,351,041 |
| Current liabilities | Employee benefit liabilities, less current portion | 49,931 | 84,921 |
| Current liabilities | Operating lease liabilities, less current portion | 1,672,155 | |
| Current liabilities | Total liabilities | 6,651,010 | 5,435,962 |
| Shareholders’ equity | Common stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026, respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively* | 29,056 | 7,324 |
| Shareholders’ equity | Treasury stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively* | -1 | -1 |
| Shareholders’ equity | Additional paid-in capital* | 80,992,006 | 65,849,822 |
| Shareholders’ equity | Accumulated deficit | -74,964,040 | -62,533,065 |
| Shareholders’ equity | Accumulated other comprehensive loss | -546,186 | -327,944 |
| Shareholders’ equity | Total consolidated Intelligent Bio Solutions Inc. equity | 5,510,835 | 2,996,136 |
| Shareholders’ equity | Non-controlling interest | -220,009 | -182,312 |
| Shareholders’ equity | Total shareholders’ equity | 5,290,826 | 2,813,824 |
| Shareholders’ equity | TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 11,941,836 | 8,249,786 |
Full release
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent
Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” and “approximately,” or other words that convey uncertainty... (truncated)rd-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the
U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release.
Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company
Contact
Intelligent
Bio Solutions Inc. info@ibs.inc
Investor
& Media Contact
Valter
Pinto, Managing Director
KCSA
Strategic Communications
PH:
(212) 896-1254
INBS@kcsa.com — Financial tables to follow — Intelligent
Bio Solutions Inc.
Consolidated
Balance Sheets
Intelligent
Bio Solutions Inc.
Consolidated
Statements of Operations and Other Comprehensive Income (Loss)